NeuroMab™ Anti-SORT1 BBB Shuttle Antibody(NRZP-1022-ZP3962)

Figure 1 shows the effect of the Sortilin antibody Antibody 45 on the binding of Sortilin PGRN.

Figure 2 shows the effect of D-region and D+Sortilin antibodies on the binding of selective small molecule ligand AF38469 to Sortilin.

Figure 3 Effects of antibodies 45 and 68 on cellular binding and endocytosis of PGRN.

Figure 4 Extracellular PGRN levels estimated by ELISA in media from sortin-overexpressing HEK cell cultures (S18).

Figure 5 shows the effect of Sortilin antibody on extracellular PGRN in neuronally differentiated iPSC cells.

Figure 6 Time-course study: Elevated plasma PGRN levels were observed following injection of antibody 45 (Panel D).

Figure 7 Dose-response study: Sortilin (45) and control antibody (Anti-Hel) were injected at different doses (4 doses: 0.1, 0.4, 2 and 10 mg/kg) and mice were sacrificed on day 2.

Figure 8 Subchronic study: Mice were treated twice weekly with 10 mg/kg of 45 and a control antibody (anti-Hel).

Figure 9 shows representative peptides covering the 45, 68 and 811 conformational epitopes.

Figure 10 shows representative peptides covering the antibody 30 conformational epitope.

Figure 11 shows representative peptides covering the antibody 30 conformational epitope.

Figure 12 shows the time course: Effect of systemic administration of Antibody 45 or PBS (50 mg/kg, 10 ml/kg, sc) 24 hours before microdialysis experiments on PRGN levels in the hippocampus of freely moving hSORT1 mice over time Over time (24 hours).

Figure 13 shows the results of pooled 24-hour dialysis: Basal PRGN in the hippocampus of freely moving hSORT1 mice was 3.3±0.3 ng/ml and 1.1±0.1 ng/ml in mab#45 and PBS-treated mice, respectively. ml, assessed by push-pull microdialysis.